

## Special Issue

# Smart Nanoparticles for Tumor-Targeted Drug Delivery

### Message from the Guest Editors

Nanoparticle drug delivery systems (NDDSs) have attracted tremendous attention in tumor-targeted drug delivery, with the fascination concerning novel properties of nanoparticles mainly stemming from the fact that nanoparticles have a huge surface area compared to microparticles or bulk materials. To control drug delivery with a very slow drug release into the blood circulation, yet with a fast drug release at tumor tissues, smart nanoparticles capable of releasing more drug molecules upon the stimulation of the tumor microenvironment are crucial for improving antitumor efficacy. This Special Issue aims to discuss the latest research progress of novel smart nanoparticles, including the design, preparation, and their applications in tumor-targeted drug delivery. This is a very useful resource for researchers who are actively involved in NDDSs. We accept original research articles, critical review papers, and commentaries providing a further understanding regarding novel smart nanoparticles for tumor-targeted drug delivery.

### Guest Editors

Prof. Dr. Zifu Li

1. National Engineering Research Center for Nanomedicine, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan 430074, China
2. Key Laboratory of Molecular Biophysics of Ministry of Education, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan 430074, China
3. Hubei Key Laboratory of Bioinorganic Chemistry and Material Medical, Huazhong University of Science and Technology, Wuhan 430074, China
4. Hubei Engineering Research Center for Biomaterials and Medical Protective Materials, Huazhong University of Science and Technology, Wuhan 430074, China

Prof. Dr. Zhiyue Zhang

Department of Pharmaceutics, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, Jinan 250012, China

### Deadline for manuscript submissions

closed (30 September 2022)



## Pharmaceutics

an Open Access Journal  
by MDPI

Impact Factor 5.5  
CiteScore 10.0  
Indexed in PubMed



[mdpi.com/si/112868](https://mdpi.com/si/112868)

*Pharmaceutics*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[pharmaceutics@mdpi.com](mailto:pharmaceutics@mdpi.com)

[mdpi.com/journal/  
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





# Pharmaceutics

---

an Open Access Journal  
by MDPI

---

Impact Factor 5.5  
CiteScore 10.0  
Indexed in PubMed



[mdpi.com/journal/  
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



## About the Journal

### Message from the Editor-in-Chief

*Pharmaceutics* (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

---

### Editor-in-Chief

Prof. Dr. Patrick J. Sinko  
Department of Pharmaceutics, Ernest Mario School of Pharmacy,  
Rutgers University, Piscataway, NJ 08854, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1  
(Pharmaceutical Science)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).